YBGJ (Yubo International Biotech) Net Margin %: 0.00% (As of Mar. 2026)


What is Yubo International Biotech Net Margin %?

Yubo International Biotech YBGJ +30.43% Net Margin % is 0.00% as of Mar. 2026. The stock has 2 warning signs investors should review. Among 818 Medical Devices & Instruments companies, Yubo International Biotech ranks worse than 98.04% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Yubo International Biotech's Net Income for the three months ended in Mar. 2026 was $-0.27 Mil. Yubo International Biotech's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Yubo International Biotech's net margin for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Yubo International Biotech's Net Margin % or its related term are showing as below:

YBGJ' s Net Margin % Range Over the Past 10 Years
Min: -59166.67   Med: -678.09   Max: -52.58
Current: -8675

YBGJ's Net Margin % is ranked worse than
98.04% of 818 companies
in the Medical Devices & Instruments industry
Industry Median: 2.06 vs YBGJ: -8675.00

Yubo International Biotech  (OTCPK:YBGJ) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Yubo International Biotech Net Margin % Related Terms

Yubo International Biotech Net Margin % Historical Data

* Premium members only.

The historical data trend for Yubo International Biotech's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Yubo International Biotech Net Margin % Chart

Yubo International Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial -123.95 -1,158.65 -197.52 -59,166.67 -8,991.67

Yubo International Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -2,175.00 0.00

YBGJ vs ECIA, GCTK, RSCF: Net Margin % Comparison

For the Medical Instruments & Supplies subindustry, Yubo International Biotech's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Yubo International Biotech Net Margin % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Yubo International Biotech's Net Margin % distribution charts can be found below:

* The bar in red indicates where Yubo International Biotech's Net Margin % falls into.


Yubo International Biotech Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Yubo International Biotech's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-1.079/0.012
=-8,991.67 %

Yubo International Biotech's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-0.273/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Yubo International Biotech (YBGJ) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Yubo International Biotech and its competitors. According to the industry distribution chart, Yubo International Biotech ranks #802 out of 818 companies in the Medical Devices & Instruments industry, placing it in the top 98%.
Is Yubo International Biotech's Net Margin % too high?
Yubo International Biotech's current Net Margin % is 0.00%. Based on the distribution chart, Yubo International Biotech ranks #802 out of 818 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Yubo International Biotech's Net Margin % compare to ECIA and GCTK?
According to the Medical Devices & Instruments industry distribution chart, Yubo International Biotech ranks #802 out of 818 companies for Net Margin %. This places Yubo International Biotech in the lower half of its industry. The industry median Net Margin % is 2.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.06, based on 818 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Yubo International Biotech and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yubo International Biotech's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yubo International Biotech stock overvalued right now?
Yubo International Biotech (YBGJ) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Yubo International Biotech (YBGJ), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Yubo International Biotech Business Description

Address No. 10 Chaoyang Park South Road, Room 1102, 11th Floor, Building 2, Chaoyang District, Beijing, CHN, 100026
Yubo International Biotech Ltd is a technology company focused on the research, development, and application of endometrial stem cells. It offers products and services under the brand VIVCELL. Its product offerings include healthcare products for the respiratory system, skincare products, hair care products, healthy beverages and male and female personal care products. It also offers stem cell-related services including cell testing and health management consulting services. The company derives its revenue from the sale of certain health management services and the sale of nebulizers containing frozen tubes with medical fluid. The nebulizers are sold directly to consumers on its online e-commerce platform.